Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel Sells 12,946 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 12,946 shares of Alphatec stock in a transaction on Monday, February 24th. The shares were sold at an average price of $10.73, for a total transaction of $138,910.58. Following the transaction, the executive vice president now owns 722,128 shares in the company, valued at $7,748,433.44. The trade was a 1.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

David Sponsel also recently made the following trade(s):

• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The shares were sold at an average price of $11.42, for a total value of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Stock Performance

Shares of ATEC opened at $11.06 on Thursday. The firm has a fifty day moving average of $10.57 and a 200-day moving average of $8.35. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -8.64 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $15.41.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. As a group, equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of Alphatec

Large investors have recently added to or reduced their stakes in the business. Comerica Bank boosted its holdings in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Alphatec during the fourth quarter worth $29,000. Nisa Investment Advisors LLC raised its position in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares during the period. Quarry LP raised its position in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 2,375 shares during the period. Finally, Newton One Investments LLC purchased a new position in Alphatec in the 4th quarter worth about $50,000. 66.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on ATEC shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. Barclays increased their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC lifted their price target on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.